BEIJING – EOC Pharmaceutical Group, of Shanghai, completed a series C financing round, bagging $71 million to advance its lead programs EOC-103 and EOC-315 for breast and gastric cancers. The round was led by Hangzhou Tigermed Consulting Co. Ltd. and its affiliated funds, TF Capital and Yingke PE. Hanne Capital and Everest Venture Capital also participated in the round. In 2017, EOC raised $32 million in a series B round. All funding participants are China-based.